JOHNSON & JOHNSON (JNJ) Earnings History
JOHNSON & JOHNSON - Q1 2026 Earnings
EXECUTIVE SUMMARY
Johnson & Johnson reported a strong first quarter with robust revenue growth driven by its Innovative Medicine and MedTech segments. The company demonstrated solid operational execution, though net earnings saw a significant decline due to a large one-time gain in the prior year's quarter.
POSITIVE HIGHLIGHTS
- •
Worldwide sales increased 9.9% to $24.1 billion, driven by strong performance in both Innovative Medicine and MedTech segments.
positive - •
Innovative Medicine segment sales grew 11.2% operationally to $15.4 billion, with strong contributions from Oncology and Neuroscience.
positive - •
MedTech segment sales increased 7.7% operationally to $8.6 billion, with growth across Cardiovascular, Surgery, Vision, and Orthopaedics.
positive - •
Operational sales growth of 6.4% globally, indicating strong underlying business performance.
positive
CONCERNS & RISKS
- •
Reported Net Earnings decreased by 52.4% to $5.2 billion, primarily due to a significant one-time gain in the prior year's quarter related to 'Other (income) expense, net'.
negative - •
Diluted EPS decreased by 52.9% to $2.14, reflecting the decline in net earnings.
negative - •
Adjusted Net Earnings decreased by 1.4% to $6.6 billion, and Adjusted Diluted EPS decreased by 2.5% to $2.70, indicating some pressure on profitability even after excluding special items.
attention - •
Imbruvica sales declined 39.1% in the US and 6.9% worldwide, indicating a significant impact from competition or patent expirations.
attention - •
Stelara sales decreased 77.6% in the US and 59.7% worldwide, likely due to biosimilar competition.
attention
FINANCIAL METRICS
MARGIN ANALYSIS
Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
REVENUE BY SEGMENT — Q1 2026 2026
VISUAL OVERVIEW
DETAILED BREAKDOWN
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Innovative Medicine | N/A | — | — | — | +7.4% |
MedTech | N/A | — | — | — | +4.6% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
EARNINGS CALL —
SPECIAL ITEMS & ADJUSTMENTS
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
MANAGEMENT COMMENTARY
Strong first-quarter performance driven by robust growth in Innovative Medicine and MedTech.
Operational sales growth of 6.4% reflects strong underlying business momentum.
Continued focus on innovation and expanding market access for key products.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
OPERATIONAL METRICS
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.